

Author Index Volume 12 (2012/2013)

The issue number is given in front of the pagination

- Agell, L., see de Muga, S. (1) 21–30
Akbulut, H., see Aktas, S.H. (3) 135–140
Akgun, N., see Aktas, S.H. (3) 135–140
Aktas, S.H., H. Akbulut, N. Akgun and F. Icli, Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: A tentative relationship between drug type and tumor cell type response (3) 135–140
Araki, Y., see Yoshitake, H. (3) 141–148
Araújo, A., see Catarino, R. (2) 65–72

Beck, A., see Joseph, S. (4,5) 177–184
Blasberg, J., see Joseph, S. (4,5) 177–184
Bocanek, O., see Faltejskova, P. (4,5) 199–204
Boonmars, T., see Rucksaken, R. (2) 81–95

Canis, M., A. Lechner, B. Mack, P. Zengel, R.P. Laubender, U. Koehler, V. Heissmeyer and O. Gires, CD133 is a predictor of poor survival in head and neck squamous cell carcinomas (2) 97–105
Catarino, R., A. Coelho, A. Nogueira, A. Araújo, M. Gomes, C. Lopes and R. Medeiros, Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population (2) 65–72
Chen, L., see Tang, X. (1) 11–19
Choi, K.Y., Y.S. Rho, K.H. Kwon, E.J. Chung, J.H. Kim, I.S. Park and D.J. Lee, ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma (3) 115–124
Chowdry, J., see Mackinder, M.A. (2) 49–64
Chung, E.J., see Choi, K.Y. (3) 115–124
Coelho, A., see Catarino, R. (2) 65–72
Corfe, B.M., see Mackinder, M.A. (2) 49–64

Dawood, S. and A.M. Gonzalez-Angulo, Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer (6) 241–250

de Muga, S., S. Hernández, M. Salido, M. Lorenzo, L. Agell, N. Juanpere, J.A. Lorente, S. Serrano and J. Lloreta, *CXCR4* mRNA overexpression in high grade prostate tumors: Lack of association with *TMPRSS2-ERG* rearrangement (1) 21–30
Ding, X., see Huang, J. (3) 107–113
Ding, Y., see Shao, N. (1) 37–47
Donington, J., see Joseph, S. (4,5) 177–184

El Aaty Shawky, A., see El-Hafez, A.A. (4,5) 149–154
El-Hafez, A.A., A. El Aaty Shawky and B. Hasan, Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma (4,5) 149–154
Endo, S., see Yoshitake, H. (3) 141–148
Evans, C.A., see Mackinder, M.A. (2) 49–64

Faltejskova, P., O. Bocanek, M. Sachlova, M. Svoboda, I. Kiss, R. Vyzula and O. Slaby, Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer (4,5) 199–204
Fan, G., see Gao, Y. (1) 31–36
Fan, L., see Zou, Z.-J. (4,5) 169–176
Feng, N.H., see Shao, N. (1) 37–47
Fu, Q., see Quan, Y. (3) 125–133
Fujiwara, H., see Yoshitake, H. (3) 141–148

Gam, L.H., see Lim, S.R. (4,5) 185–198
Gao, C., see Huang, J. (3) 107–113
Gao, S., see Huang, J. (3) 107–113
Gao, Y., J. Wang and G. Fan, NPRL2 is an independent prognostic factor of osteosarcoma (1) 31–36
Gires, O., see Canis, M. (2) 97–105
Goel, R., see Kashyap, M.K. (1) 1–9
Goldberg, J.D., see Joseph, S. (4,5) 177–184
Gomes, M., see Catarino, R. (2) 65–72
Gong, Y., Significance of biomarker discordance in breast cancer from the pathologist's perspective (6) 207–218

- Gonzalez-Angulo, A.M., see Dawood, S. (6) 241–250
 Gooi, B.-H., see Lim, S.R. (4,5) 185–198
- Harrington, R., see Joseph, S. (4,5) 177–184
 Harsha, H.C., see Kashyap, M.K. (1) 1–9
 Hasan, B., see El-Hafez, A.A. (4,5) 149–154
 Heissmeyer, V., see Canis, M. (2) 97–105
 Hernández, S., see de Muga, S. (1) 21–30
 Hiraku, Y., see Rucksaken, R. (2) 81–95
 Hirsch, N., see Joseph, S. (4,5) 177–184
 Hua, L.X., see Shao, N. (1) 37–47
 Huang, J., C. Gao, X. Ding, S. Qu, L. Liu, W. Wu, L. Zhang, J. Zhao and S. Gao, MGB-based one-step multiplex real-time PCR method for rapid detection of HPV (3) 107–113
- Icli, F., see Aktas, S.H. (3) 135–140
 Ishikawa, H., see Yoshitake, H. (3) 141–148
- Jiang, W.Y., see Shao, N. (1) 37–47
 Joseph, S., R. Harrington, D. Walter, J.D. Goldberg, X. Li, A. Beck, T. Litton, N. Hirsch, J. Blasberg, M. Slomiany, W. Rom, H. Pass and J. Donington, Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population (4,5) 177–184
 Juanpere, N., see de Muga, S. (1) 21–30
- Kashyap, M.K., H.A. Pawar, S. Keerthikumar, J. Sharma, R. Goel, R. Mahmood, M.V. Kumar, K.V.V. Kumar, A. Pandey, R.V. Kumar, T.S.K. Prasad and H.C. Harsha, Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma (1) 1–9
 Keerthikumar, S., see Kashyap, M.K. (1) 1–9
 Khan, S., see Lower, E.E. (6) 219–230
 Khoontawad, J., see Rucksaken, R. (2) 81–95
 Kim, D.S., see Na, Y. (2) 73–79
 Kim, J.H., see Choi, K.Y. (3) 115–124
 Kiss, I., see Faltejskova, P. (4,5) 199–204
 Koehler, U., see Canis, M. (2) 97–105
 Kumar, K.V.V., see Kashyap, M.K. (1) 1–9
 Kumar, M.V., see Kashyap, M.K. (1) 1–9
 Kumar, R.V., see Kashyap, M.K. (1) 1–9
 Kwon, K.H., see Choi, K.Y. (3) 115–124
- Laubender, R.P., see Canis, M. (2) 97–105
 Lechner, A., see Canis, M. (2) 97–105
 Lee, D.J., see Choi, K.Y. (3) 115–124
 Lee, S.M., see Na, Y. (2) 73–79
 Li, F., see Tang, X. (1) 11–19
 Li, H., see Tang, X. (1) 11–19
 Li, J.-Y., see Zou, Z.-J. (4,5) 169–176
 Li, X., see Joseph, S. (4,5) 177–184
 Lim, S.R., B.-H. Gooi and L.H. Gam, Identification of low abundance proteins in colorectal cancer tissues (4,5) 185–198
 Litton, T., see Joseph, S. (4,5) 177–184
 Liu, L., see Huang, J. (3) 107–113
 Lloreta, J., see de Muga, S. (1) 21–30
 Lopes, C., see Catarino, R. (2) 65–72
 Lorente, J.A., see de Muga, S. (1) 21–30
 Lorenzo, M., see de Muga, S. (1) 21–30
 Lower, E.E. and S. Khan, Biomarker discordance: Why it occurs and why it is important (6) 219–230
- Mack, B., see Canis, M. (2) 97–105
 Mackinder, M.A., C.A. Evans, J. Chowdry, C.A. Stanton and B.M. Corfe, Alteration in composition of keratin intermediate filaments in a model of breast cancer progression and the potential to reverse hallmarks of metastasis (2) 49–64
 Mahmood, R., see Kashyap, M.K. (1) 1–9
 Maruyama, M., see Yoshitake, H. (3) 141–148
 Medeiros, R., see Catarino, R. (2) 65–72
 Moussa, O., C. Purdie, S. Vinnicombe and A.M. Thompson, Biomarker discordance: Prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility (6) 231–239
- Na, Y., S.M. Lee, D.S. Kim and J.Y. Park, Promoter methylation of Wnt antagonist *DKK1* gene and prognostic value in Korean patients with non-small cell lung cancers (2) 73–79
 Niikura, N. and N.T. Ueno, Change in HER2 status during breast tumor progression (6) 251–255
 Nogueira, A., see Catarino, R. (2) 65–72
 Nojima, M., see Yoshitake, H. (3) 141–148
- Pairojkul, C., see Rucksaken, R. (2) 81–95
 Pandey, A., see Kashyap, M.K. (1) 1–9
 Park, I.S., see Choi, K.Y. (3) 115–124
 Park, J.Y., see Na, Y. (2) 73–79
 Pass, H., see Joseph, S. (4,5) 177–184
 Pawar, H.A., see Kashyap, M.K. (1) 1–9
 Pinlaor, P., see Rucksaken, R. (2) 81–95
 Pinlaor, S., see Rucksaken, R. (2) 81–95
 Prasad, T.S.K., see Kashyap, M.K. (1) 1–9
 Purdie, C., see Moussa, O. (6) 231–239

- Qiao, D., see Shao, N. (1) 37–47
- Qu, S., see Huang, J. (3) 107–113
- Quan, Y., Y. Yan, X. Wang, Q. Fu, W. Wang, J. Wu, G. Yang, J. Ren and Y. Wang, Impact of cell dissociation on identification of breast cancer stem cells (3) 125–133
- Ren, G., see Tang, X. (1) 11–19
- Ren, J., see Quan, Y. (3) 125–133
- Rho, Y.S., see Choi, K.Y. (3) 115–124
- Rom, W., see Joseph, S. (4,5) 177–184
- Roytrakul, S., see Rucksaken, R. (2) 81–95
- Rucksaken, R., J. Khoontawad, S. Roytrakul, P. Pinlaor, Y. Hiraku, C. Wongkham, C. Pairojkul, T. Boonmars and S. Pinlaor, Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma (2) 81–95
- Sachlova, M., see Faltejskova, P. (4,5) 199–204
- Salido, M., see de Muga, S. (1) 21–30
- Serrano, S., see de Muga, S. (1) 21–30
- Shao, N., W.Y. Jiang, D. Qiao, S.G. Zhang, Y. Wu, X.X. Zhang, L.X. Hua, Y. Ding and N.H. Feng, An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies (1) 37–47
- Sharma, J., see Kashyap, M.K. (1) 1–9
- Slaby, O., see Faltejskova, P. (4,5) 199–204
- Slomiany, M., see Joseph, S. (4,5) 177–184
- Staton, C.A., see Mackinder, M.A. (2) 49–64
- Suzuki, F., see Yoshitake, H. (3) 141–148
- Svoboda, M., see Faltejskova, P. (4,5) 199–204
- Takamori, K., see Yoshitake, H. (3) 141–148
- Tang, X., X. Yin, T. Xiang, H. Li, F. Li, L. Chen and G. Ren, Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer (1) 11–19
- Thompson, A.M., see Moussa, O. (6) 231–239
- Ueno, N.T., see Niikura, N. (6) 251–255
- Vinnicombe, S., see Moussa, O. (6) 231–239
- Vyzula, R., see Faltejskova, P. (4,5) 199–204
- Walter, D., see Joseph, S. (4,5) 177–184
- Wang, J., see Gao, Y. (1) 31–36
- Wang, L., see Zou, Z.-J. (4,5) 169–176
- Wang, W., see Quan, Y. (3) 125–133
- Wang, X., see Quan, Y. (3) 125–133
- Wang, Y., see Quan, Y. (3) 125–133
- Wongkham, C., see Rucksaken, R. (2) 81–95
- Wu, J., see Quan, Y. (3) 125–133
- Wu, W., see Huang, J. (3) 107–113
- Wu, Y., see Shao, N. (1) 37–47
- Xiang, T., see Tang, X. (1) 11–19
- Xu, W., see Zou, Z.-J. (4,5) 169–176
- Yan, Y., see Quan, Y. (3) 125–133
- Yang, G., see Quan, Y. (3) 125–133
- Yang, S., see Zou, Z.-J. (4,5) 169–176
- Yin, X., see Tang, X. (1) 11–19
- Yokoi, H., see Yoshitake, H. (3) 141–148
- Yoshida, K., see Yoshitake, H. (3) 141–148
- Yoshikawa, H., see Yoshitake, H. (3) 141–148
- Yoshitake, H., H. Yokoi, H. Ishikawa, M. Maruyama, S. Endo, M. Nojima, K. Yoshida, H. Yoshikawa, F. Suzuki, K. Takamori, H. Fujiwara and Y. Araki, Overexpression of TEX101, a potential novel cancer marker, in head and neck squamous cell carcinoma (3) 141–148
- Zeng, B., see Zhang, C. (4,5) 155–167
- Zengel, P., see Canis, M. (2) 97–105
- Zhang, C., Y. Zhao and B. Zeng, Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2 (4,5) 155–167
- Zhang, L., see Huang, J. (3) 107–113
- Zhang, L.-N., see Zou, Z.-J. (4,5) 169–176
- Zhang, R., see Zou, Z.-J. (4,5) 169–176
- Zhang, S.G., see Shao, N. (1) 37–47
- Zhang, X.X., see Shao, N. (1) 37–47
- Zhao, J., see Huang, J. (3) 107–113
- Zhao, Y., see Zhang, C. (4,5) 155–167
- Zou, Z.-J., L. Fan, L. Wang, R. Zhang, L.-N. Zhang, S. Yang, J.-Y. Li and W. Xu, Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia (4,5) 169–176